Wednesday, September 5, 2018

Introducing IvyGene: "Patient-Friendly" Advancement in Early Cancer Detection

 "...the term 'cancer' is not a singular enemy; its a single term to represent hundreds of different cancer types-- all unique to their location in the body and their origin, and that makes screening/treating them a very specialized and a highly customized procedure."  Howard Prince, research specialist & patient advocate

Early detection and prevention pursuits have driven our medical community to invest heavily on the advancement of cancer screenings for every individual type of cancer.  So exists specialized scanning processes and tools such as colonoscopy, tomography, mammograms, mri's, PSA tests, PET Scans, skin exams- just to name a few.

Recently, a new form of blood test by LAM (Laboratory for Advanced Medicine) can confirm the presence of cancer as early as stage 1. It provides measurable data in the form of a score to make it easier to understand- while confirming the presence of cancer early, when it can be more easily managed and treated.   The score can be used as a baseline to measure treatment effectiveness.

Among the growing list of cancer treatment professionals and practices who subscribe to IvyGene’ s innovative screening capacity is clinical immunologist Dr. Jesse Stoff of Integrative Medicine of NY in Westbury.  As an integrative practitioner, Dr. Stoff is committed to staying on top of the latest in cancer treatment solutions available.  "IvyGene is similar to a liquid biopsy in terms of the technology. It is based on next-gen technology & next-gen sequencing," says Dr. Stoff. "(For my purposes), I use this test for people who don't have signs of cancer because it takes on average 10 years for cancer to go from a few cancer cells into a destructive tumor. And during that 10 year period of time these abnormal cells are firing off pieces of genetic material into the blood stream as these cells die. And die they do because cancer cells are genetically unstable. That's part of the definition of cancer. The problem is they multiply faster than they die. So, that's how you get in trouble. As the cells die, they release material into the bloodstream that the IvyGene test is designed to pick up and act as an early warning where something is starting to grow someplace you need to pay attention to."

According to an interview with LAM representative Caleb Allen, "...our mission is to make cancer testing available and affordable for everyone. We work closely with thousands of physicians nationwide to provide early cancer confirmation and save lives sooner. Unlike many genetic tests that use DNA to determine the propensity or possibility of developing cancer over time, the IvyGene test confirms actual disease presence at the time of testing."

Physicians who accepted the use of IvyGene to confirm cancer presence typically suggests it's use if the patient:

  • has genetic propensity for development of cancer
  • has suspicious imaging (PET, Mammo, CT) and needs confirmation
  • has had cancer in the past, IvyGene monitors for remission
  • is undergoing cancer treatment now
  • is experiencing under-diagnosed health issues

SCIENCE: Using highly advanced technology, the team identified specific gene targets in human DNA that correlate with cancer presence. Then, the IvyGene technology measures certain ratios at those specific gene targets. This results in a simple score that is either (a) elevated and consistent with the presence of cancer or (b) “normal” and not consistent with cancer presence.  

 See video insert from Overview of theIvyGene Science

A recent trend in testing kits commercially distributed to physicians and/or direct to the consumer, are changing the way patients are receiving treatment and billed.  Packaging lab testing services from anywhere in the country through a portable (mailable) transport kit is a most cost effective and efficient way to expand public access to and from any specialized lab service(s).  This kit-concept allows access of a specialized lab from anywhere in the country to partner with any clinic or practice.  This streamlines the retrieval and delivery of acquired blood samples to the designated lab and greatly eliminating a number of steps and "overhead" expenses.  Instead of building a high-priced lab in each city, county or state, there is now just once central lab for the entire country.

A firefighter's emergency rescue work often brings exposure to a wide range of hazardous (and potentially carcinogenic) substances. A recent study from the IAFF shows a significant percentage of firefighters will be diagnosed with cancer at some point during their lifetime. Others studies indicate that firefighters are up to 2X at risk for developing certain cancers. It is for this reason that and its clinical partners including Integrative Medicine of NY  helped to publicly introduce genetic testing protocols and such scanning/diagnostic innovations as the IvyGene solution to the community.  Originally founded for 9/11 survivors and victims, the 911CancerScan program brings informational and resource access to any and all first responders to address this health risk.  See the Firefighter Cancer Support Network website for more information. Also see the recent report from WFAA, Dallas, regarding cancer and prevention policies for Firefighters:


Jesse A. Stoff is a highly-credentialed medical expert studying all medical remedies in pursuit of resolving the most challenging health issues of our time. In many circles, he is recognized for his 35+ years of dedicated work in immunology and advanced clinical research in modern CANCER treatments. He has spoken worldwide in some of the most sought-after medical conferences about his experiences and analyses on the study of human disease. His integrative practice (INTEGRATIVE MEDICINE OF NY, Westbury, NY) has been continually providing all patients with the many comprehensive clinical options and modalities available- including "ONCO-IMMUNOLOGY", the science of battling cancer cells and reversing pre-cancerous conditions through a complete prevention program that has earned him great success in this field.  For more information, visit:

Disclaimer & Copyright Notice: The materials provided on this website/web-based article are copyrighted and the intellectual property of the publishers/producers (The NY Cancer Resource Alliance/IntermediaWorx inc. and Bard Diagnostic Research & Educational Programs). It is provided publicly strictly for informational purposes within non-commercial use and not for purposes of resale, distribution, public display or performance. Unless otherwise indicated on this web based page, sharing, re-posting, re-publishing of this work is strictly prohibited without due permission from the publishers.  Also, certain content may be licensed from third-parties. The licenses for some of this Content may contain additional terms. When such Content licenses contain additional terms, we will make these terms available to you on those pages (which his incorporated herein by reference).The publishers/producers of this site and its contents such as videos, graphics, text, and other materials published are not intended to be a substitute for professional medical advice, diagnosis, or treatment. For any questions you may have regarding a medical condition, please always seek the advice of your physician or a qualified health provider. Do not postpone or disregard any professional medical advice over something you may have seen or read on this website. If you think you may have a medical emergency, call your doctor or 9-1-1 immediately.  This website does not support, endorse or recommend any specific products, tests, physicians, procedures, treatment opinions or other information that may be mentioned on this site. Referencing any content or information seen or published in this website or shared by other visitors of this website is solely at your own risk. The publishers/producers of this Internet web site reserves the right, at its sole discretion, to modify, disable access to, or discontinue, temporarily or permanently, all or any part of this Internet web site or any information contained thereon without liability or notice to you.


HOW EFFECTIVE ARE STRATEGIES TO LOWER PSA READINGS?   By: Dr. Roberta Kline PSA, or prostate-specific antigen, is a protein produced by pros...